Results 241 to 250 of about 195,409 (316)

Data Sheet 1_Case Report: Menstrual cycle–related psychosis in bipolar I disorder, remitting with a combined oral contraceptive.pdf

Shota Hanyu (22788761), Kei Yoshimoto (22788764), Nobuo Shimizu (22788767)   +2 more
openalex   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Retina in Clinical High-Risk and First-Episode Psychosis. [PDF]

Schizophr Bull
Demirlek C, Arslan B, Eyuboglu MS, Yalincetin B, Atas F, Cesim E, Demir M, Uzman Ozbek S, Kizilay E, Verim B, Sut E, Baykara B, Kaya M, Akdede BB, Bora E.   +14 more
europepmc   +1 more source

Predicting Response to Pro‐Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are often associated with persistent cognitive deficits that impair psychosocial functioning. While pro‐cognitive interventions show promise, trial findings are inconsistent, potentially due to baseline factors influencing treatment response.
Dimosthenis Tsapekos, Michail Kalfas, Johanna M. Schandorff, Caterina del Mar Bonnin, Christopher R. Bowie, Vicent Balanzá‐Martínez, Katherine E. Burdick, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Gregor Hasler, Lars V. Kessing, Hanne L. Kjærstad, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martinez‐Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul R. A. Stokes, Tomiki Sumiyoshi, Ivan J. Torres, Tamsyn E. Van Rheenen, Lakshmi N. Yatham, Jeff Zarp, Allan H. Young, Eduard Vieta, Kamilla W. Miskowiak   +30 more
wiley   +1 more source

Associations Between Genetic Risk, Physical Activities, and Distressing Psychotic-like Experiences. [PDF]

Schizophr Bull
Ku BS, Yuan Q, Arias-Magnasco A, Lin BD, Walker EF, Druss BG, Ren J, van Os J, Guloksuz S.   +8 more
europepmc   +1 more source

Qualitative Content Analysis of What Constitutes Effectual Group/Support Therapyfor Individuals Diagnosed with Schizophrenia/Psychosis Spectrum Illnesses: Client’s Perspective

, 2015
Michelle Good
openalex   +1 more source

No Effect of Low‐Dose Aspirin Versus Placebo as Add‐On Treatment in Bipolar Disorder—Results From a Randomised Controlled Trial (the A‐Bipolar RCT)

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Robust evidence associates immunoinflammatory dysfunction and bipolar disorder (BD), with immune dysregulation present in patients newly diagnosed with BD. This suggests that anti‐inflammatory agents, like low‐dose aspirin (LDA), might be repurposed in the treatment of early‐stage BD.
Caroline Fussing Bruun, Helle B. Krogh, Jeff Zarp, Julie Ravneberg Stokholm, Julie Lyng Forman, Kamilla Woznica Miskowiak, Annamaria Giraldi, Maj Vinberg, Maria Faurholt‐Jepsen, Lars Vedel Kessing   +9 more
wiley   +1 more source

Polygenic risk for schizophrenia predicting test-measured and self-reported cognitive performance in individuals without psychosis. [PDF]

BMC Psychiatry
Rosenqvist E, Lyytikäinen LP, Sormunen E, Kähönen M, Raitakari O, Hietala J, Pahkala K, Lehtimäki T, Keltikangas-Järvinen L, Rovio S, Saarinen A.   +10 more
europepmc   +1 more source